NDAORALTABLETPriority Review
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
THIOLA (tiopronin) by Mission Therapeutics is cystine disulfide reduction [moa]. Approved for cystinuria. First approved in 1988.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THIOLA (tiopronin) is an oral reducing agent approved in 1988 for cystinuria, a rare genetic disorder causing cystine kidney stone formation. It works by reducing cystine disulfide bonds to form soluble complexes, lowering urinary cystine concentration and preventing stone recurrence.
$0.003BPart D
LOE Approaching2mo to LOEDeclining market opportunity with minimal Part D claims signals team contraction and focus on patient retention strategies pre-generic entry.
Mechanism of Action
Cystine Disulfide Reduction
Pharmacologic Class:
Reducing and Complexing Thiol
Indications (1)
Career Relevance
THIOLA presents minimal career opportunity with zero linked job openings and declining commercial investment. Working on this product offers limited advancement potential given imminent generic entry and small patient population.
Company
Worked on THIOLA at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.